|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM295299541 |
| 003 |
DE-627 |
| 005 |
20231225083347.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201808325
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0984.xml
|
| 035 |
|
|
|a (DE-627)NLM295299541
|
| 035 |
|
|
|a (NLM)30907460
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Fu, Lian-Hua
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Glucose Oxidase-Instructed Multimodal Synergistic Cancer Therapy
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.07.2019
|
| 500 |
|
|
|a Date Revised 30.09.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a ErratumIn: Adv Mater. 2020 Jul;32(28):e2003130. - PMID 32662931
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a Over the past 3 years, glucose oxidase (GOx) has aroused great research interest in the context of cancer treatment due to its inherent biocompatibility and biodegradability, and its unique catalytic properties against β-d-glucose. GOx can effectively catalyze the oxidation of glucose into gluconic acid and hydrogen peroxide. This process depletes oxygen levels, resulting in elevated acidity, hypoxia, and oxidative stress in the tumor microenvironment. All of these changes can be readily harnessed to develop a multimodal synergistic cancer therapy by combining GOx with other therapeutic approaches. Herein, the representative studies of GOx-instructed multimodal synergistic cancer therapy are introduced, and their synergistic mechanisms are discussed systematically. The current challenges and future prospects to advance the development of GOx-based nanomedicines in this cutting-edge research area are highlighted
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a cancer treatment
|
| 650 |
|
4 |
|a glucose oxidase
|
| 650 |
|
4 |
|a starvation therapy
|
| 650 |
|
4 |
|a synergistic therapy
|
| 650 |
|
7 |
|a Glucose Oxidase
|2 NLM
|
| 650 |
|
7 |
|a EC 1.1.3.4
|2 NLM
|
| 650 |
|
7 |
|a Glucose
|2 NLM
|
| 650 |
|
7 |
|a IY9XDZ35W2
|2 NLM
|
| 700 |
1 |
|
|a Qi, Chao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hu, Yan-Ru
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Jing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Peng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 31(2019), 21 vom: 23. Mai, Seite e1808325
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:31
|g year:2019
|g number:21
|g day:23
|g month:05
|g pages:e1808325
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201808325
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 31
|j 2019
|e 21
|b 23
|c 05
|h e1808325
|